Replies to post #202776 on Biotech Values

[biomaven0]

One big caution is that Parkinsons trials are notoriously tricky - there can be a big placebo effect and there have been a litany of failed Phase IIIs after successful Phase IIs:

http://www.quintiles.com/blog/parkinsons-disease-and-the-placebo-effect

Here it is a bit worrying that "average total daily time of troublesome dyskinesia was not increased in one group and was decreased by 42% in the second group" - that perhaps suggests something going on with their trial design.

Peter

[DewDiligence]

NTEC sells 2.29M shares @$4.40—a 7% discount to yesterday’s close:

http://finance.yahoo.com/news/intec-pharma-announces-10-million-130000033.html

The $10M of gross proceeds won’t last very long, LOL.